双环醇对CpG-ODN诱导的肝损伤的保护作用及机制研究
|
摘要
病毒性肝炎(virus hepatitis)传染性强,发病率高,流行范围广,是全球最主要的传染病之一。病毒性肝炎肝损伤主要由免疫介导,在肝脏局部,肝细胞受HBV感染后激活免疫系统,产生炎症与化学趋化因子,将炎症、淋巴细胞活化并募集至肝脏,这些炎症和淋巴细胞的浸润如果导致过强的免疫反应,则最终引起肝组织的损伤。因此,调节机体免疫反应和抑制肝脏炎症是乙型肝炎治疗的重要策略之一。
双环醇(6-甲氧羰基-6'-羟甲基-2,3,2',3'-二亚甲基二氧基-4,4'-二甲氧基联苯)由中国医学科学院药物研究所刘耕陶院士和张纯贞教授合作的科研小组历经15年艰辛研制成功,该药降低转氨酶作用显著,对肝细胞具有较好的保护作用,并具有抗肝纤维化的作用,长期使用无明显不良反应。双环醇的问世为病毒性肝炎的治疗提供了一种新的安全、有效的辅助治疗药物,其药理基础和作用机制均值得继续深入研究。迄今为止,已有大量动物实验证明,双环醇对四氯化碳(CCl_4)、D-氨基半乳糖、对乙酰氨基酚、脂多糖(LPS)和刀豆蛋白A(ConA)等化学物质诱导的肝损伤均有保护作用,作用机制涉及抑制氧化和免疫损伤、细胞凋亡和细胞膜稳定等。但尚缺乏双环醇对病毒感染造成的肝脏炎症的保护作用及其机制的研究。
近年来关于病原体相关分子模式(Pathogen-associated molecular patterns,PAMPs)的研究进展表明,激活高等动物天然免疫应答的PAMPs广泛存在于病原体细胞表面,识别PAMPs是以模式识别受体(Pattern recognition receptors,PPRs),Toll样受体(Toll-like receptors,TLRs)介导的。细菌和病毒的DNA作为一种PAMPs能被机体识别并激发免疫应答,是因为其基因组中的一段以非甲基化CpG二核苷酸为核心的高保守序列,即CpG基序(CpG motif)。机体免疫系统通过TLR9(Toll-like receptor 9)特异识别细菌和病毒DNA中的CpG基序并形成受体复合物后,通过髓性分化因子88(myeloid differentiation factor 88,MyD 88)依赖途径,激活NF-κB(nuclear factor-κB)通路和应激酶通路等信号转导通路,促进机体产生Th1型细胞应答和分泌炎症因子,当炎症因子过度释放时,则造成宿主的炎症或损伤。研究证实人工合成的含一个或数个非甲基化CpG基序的寡聚脱氧核糖核酸(CpGoligodeoxynucleotides,CpG-ODNs),也具有和细菌及病毒DNA中CpG基序一样的免疫刺激效应。因此,CpG-ODNs可用以模拟细菌和病毒等微生物病原侵入机体所引发的免疫反应状态,构建相应的疾病模型。
目前已有研究小组构建了CpG-DNA/LPS以及CpG-DNA/D-GalN诱导的小鼠肝损伤模型,为我们进一步研究病毒感染后的肝脏炎症免疫病理提供了可能的模型。本研究中,我们用CpG-ODN/D-GalN造成小鼠肝损伤,模拟小鼠感染DNA病毒后所引起的肝脏炎症反应,来研究双环醇的保护作用和机制。根据CpG-ODN的免疫活性具有种属特异性的特征,第一部分研究中,我们以对小鼠具有最佳免疫效果的CpG1826构建小鼠肝损伤模型;第二部分研究中,则以对人类最具免疫效应的CpG2006模拟病毒刺激人正常细胞株L02细胞,从整体动物和离体细胞两个水平研究双环醇对CpG-ODN造成的免疫性炎症的保护作用,及其对TLR9介导的信号通路分子的活化和细胞因子分泌的作用。
1.双环醇对CpG-ODN/D-GalN诱导的小鼠肝损伤的保护作用及其机制
目的:用CpG-ODN诱导D-GalN致敏的小鼠肝脏炎症,研究双环醇的保护作用及可能的机制。
方法:BALB/C小鼠随机分组,每组8只。第1至5天每天一次给小鼠灌胃300mg/kg和100mg/kg双环醇或溶剂;第5天给药后2小时由尾静脉注射CpG-ODN(1826)20μg/D-GalN20mg/只,模型组仅在第5天尾静脉注射CpG-ODN(1826)20μg/D-GalN20mg/只。12小时后处死小鼠并留取标本。光镜观察肝脏损伤的程度;生物化学法测定血清中ALT;ELISA法测定血清及肝脏组织匀浆中细胞因子TNF-α,IL-18和IFN-γ及趋化因子MCP-1,MIP-lα和RANTES的水平;免疫组化法检测肝脏中TLR9表达;Westernblot方法测定NF-κB及MAPKs信号途径相关分子,包括p65,p38和Erk1/2的变化。
结果:模型组小鼠血清ALT为557.33±69.51(U/L),比正常组小鼠ALT高6倍;双环醇100mg/kg和300mg/kg组的ALT分别为227.67±55.59和138.45±22.52(U/L),与模型组相比分别降低59.1%和75.2%;肝脏组织病理切片结果显示,双环醇能减少肝脏炎症细胞浸润及肝细胞的溶解性坏死,减轻肝脏的损伤程度;双环醇100mg/kg和300mg/kg组血清中的细胞因子TNF-α、IL-18和IFN-γ的水平和趋化因子MCP-1、MIP-1α和Rantes的水平均显著低于模型组,且具有剂量相关性。其中血清中TNF-α降低35.6%和72.4%;IL-18降低21.80%和47.4%;IFN-γ降低30.90%和63.3%,MCP-1降低30.5%和72.6%,MIP-1α降低28.7%和38.2%,Rantes降低25.4%和64.5%,都具有显著差异;同时,双环醇对小鼠肝脏组织中的细胞因子和趋化因子也有类似的作用;免疫组化结果显示,双环醇处理组小鼠肝脏内TLR9表达明显少于模型组;Western blot结果则表明,双环醇组p-NF-κB-p65、p-MAPK-p38和p-MAPK-Erkl/2的表达明显低于模型组。
结论:双环醇能够抑制CpG-ODN/D-GalN诱导的小鼠肝脏炎症,其主要机制可能是通过参与小鼠的免疫调节作用,抑制炎症因子TNF-α,IL-18,IFN-γ的过量表达,同时抑制TLR9介导的信号通路中的有关分子的活化,通过参与小鼠免疫调节,从多方面对CpG-ODN诱导的小鼠肝损伤起到保护作用。
2.双环醇对CpG-DNA诱导的L02细胞TLR9表达及炎症、趋化因子分泌的抑制作用及其分子机制
研究表明,炎症发生时,肝实质细胞也参与了机体的免疫反应,能对炎症信号作出反应,分泌一些炎症细胞因子和趋化因子,并通过作用于临近的肝细胞、枯否氏细胞、内皮细胞和浸润到肝脏的白细胞等发起、扩大和改变炎症反应。CpG-ODN可直接作用于肝实质细胞,上调肝细胞上的粘附分子和共刺激分子,从而使肝细胞具有了类似于抗原递呈细胞的功能,从而打破了机体的免疫耐受,对肝脏造成炎症性损伤。因此,本部分研究中,我们以正常人肝细胞株L02作为研究对象,研究双环醇对CpG-ODN刺激后的L02细胞分泌细胞因子、趋化因子及TLR9表达等的影响。
目的:以CpG2006模拟双链DNA病毒刺激L02细胞并观察双环醇对L02细胞分泌炎症、趋化因子,以及对细胞内TLR9表达的影响,研究双环醇对与炎症作用相关的分子的调节作用和机制。
方法:用不同浓度双环醇(0.01,0.1,0.5mM)与L02细胞温孵2小时后,加入浓度为10μg/ml CpG-ODN2006,继续培养18小时,模型组仅加入10μg/mlCpG-ODN2006。用ELISA法测定培养上清中TNF-α和IL-18及趋化因子MCP-1,RANTES和MIP-1α等水平;Western blot法和流式细胞术测定L02细胞内TLR9的表达;Western blot法测定细胞内p-NF-κB p65、p -p38-MAPK,pErk1/2-MAPK的变化。
结果:双环醇能够剂量依赖性地抑制CpG-ODN诱导的L02细胞趋化因子的释放和TNF-α等细胞因子的分泌,其中双环醇0.5mM组和模型组相比,TNF-α、IL-18、MCP-1、MIP-1α和Rantes分别降低77.9%,88.7%,74.6%,63.3%和64.0%。Werstern blot和流式细胞术结果一致表明,双环醇0.5mM和0.1mM能够下调L02细胞内经ODN诱导表达的TLR9,同时,还能抑制相关NF-κB通路蛋白p65和MAPK通路相关蛋白p38及ERK1/2的磷酸化。
结论:双环醇能明显抑制CpG-ODN诱导的人肝细胞株L02炎症因子和趋化因子的释放与分泌,并且抑制L02细胞内TLR9的表达及相关NF-κB和MAPK信号传导途径分子的磷酸化活性。
综上,本课题首次研究了双环醇对CpG-ODN诱导的小鼠肝损伤的保护作用,并从整体动物水平和离体细胞水平研究了双环醇对肝细胞的保护作用机制。结果表明,双环醇能显著降低CpG-ODN诱导上升的小鼠血清转氨酶并改善肝脏病理情况。其机制可能与双环醇既参与机体的免疫调节,又对肝细胞有直接的保护作用有关。双环醇在体内能抑制小鼠血清和肝组织中炎症因子(TNF-α,IL-18,IFN-γ)和趋化因子MCP-1,MIP-1α,和RANTES的水平;同时也能直接抑制体外培养的L02细胞分泌这些因子。同时,双环醇还能下调L02细胞内TLR9的表达及其信号途径所涉及的信号转导分子如NF-κB-p65,MAPK-p38和ERK1/2的活化。因此,双环醇可以从多途径减轻CpG-ODN对肝脏造成的损伤,从而达到治疗肝炎的效果。这些研究结果也提示,双环醇抗肝细胞炎症的作用有免疫学机制的介入,为解释双环醇在临床上治疗肝炎的分子机制提供了更多的的理论依据。
Chronic viral hepatitis is a worldwide disease,in particular,the incidence of chronic viral hepatitis B(CHB) in China is the highest in the world.Around 25%to 40% of the CHB population die from hepatocirrhosis or liver cancer leaded by hepatitis. Although many drugs have been used in the treatment of CHB and chronic viral hepatitis C patients,among them,interferon -2αand Lamivudine are widely used. However,there is a high rebound rate of HBV-DNA after withdrawal of lamivudine, and the side effects of interferon-2αand Lamivudine are unacceptable.Therefore,it is an urgent need to develop effective and safe new drugs to treat chronic viral hepatitis in China.
Virus of hepatitis B does not damage hepatocyte directly.However,T cell-mediated immune responses play an essential role in hepatocellular injury induced by autoimmune hepatitis,viral infection,and hepatotoxines.When effection happened, chemokines and cytokines were produced at the sites of inflammation and play an essential role in the recruitment of particular cell types that infiltrate and participate in the pathologic lesions,then hepatitis injury develops with infiltratin and/or proliferation of T cells and macrophages.Therefore,to modulate and inhibit inflammation in liver is one of the most important therapy strategies of treatment of CHB.
Bicyclol,4,4'-dimethoxy-5,6,5',6'-bis(dimethylene-dioxy)-2-hydroxymethyl-2'-m ethoxy carbonyl biphenyl) is a novel synthetic anti-hepatitis drug for the treatment of chronic hepatitis B patients in China.Numerous reports have shown that Bicyclol has protective effect against various forms of acute and chronic experimental liver injury, such as liver injury induced by carbon tetrachloride,acetaminophen,D-galactosamine, concanavalin and alcohol.Bicyclol excerts its anti-inflammatory effect thgough reflecting the function of neutrophils,monocytes or macrophages,It has been reported that the hepatoprotective mechanisms of Bicyclol involve the clearance of reactive oxygen species,regulation of cytokine secretion,and inhitition of apotosis induced by immunological injury,etc.
The purpose of the present study was to determine whether bicyclol had protective effect on liver injury induced by CpG-ODN,a rodent model represents early pathological changes in viral hepatitis,and investigate related mechanisms on cytokine expression,TLR9 expression and NF-κB& MAPK signal pathway.The results in vivo and in vitro demonstrated that oral administration of bicyclol significantly ameliorated liver injury by reducing the production of inflammatory cytokines and chemokines,and inhititing TLR9 and NF-κB& MAPK signal transduction caused by CpG-ODN.
1.Bicyelol protects mice from CpG-ODN -induced hepatitis and its mechanism
The innate immune cells recognize conserved molecular patterns present in microbes(pathogen-associated molecular patterns through a family of proteins known as toll-like receptors(TLRs) that function as pattern recognition receptors and are therby activated to exert various effector functions,including secretion of pro-inflammatory cytokines and mediators such as TNF-α,IL-6,IL-12,and nitric oxide.Production of inflammatory mediators and pro-inflammatory cytokines by innate immune cells is indispensable for the efficient control of growth and dissemination of invading pathogens.However,excessive and uncontrolled production of inflammatory medicators and pro-inflammatory cytokines caused by bacterial infection is potentially harmful to the host and may lead to sever systematic inflammatory complications.
Unmethylated CpG dinucleotides in particular sequence contexts(CpG motifs, GACGTT for murine and GTCGTT for human) in bacterial DNA are capable of activationg innate immune cells and are one of the well studied pathogen-associated molecular patterns.The ability of bacterial DNA to activate innate immunity can be mimicked by synthetic oligodexynucleotides containing the unmethylated CpG motif. This unmethylated CpG motif containing bacterial DNA and synthetic oligodeoxynucleotides(CpG DNA) are endocytosed and then recognized as a conserved molecular patern by a pattern recognition receptor TLR9 in an endosomal compartment of antigen-presenting cells in the vertebrate innate immune system.
Upon recognition of CpG DNA,TLR recruits the adaptor molecule,myeloid differentiation factor 88(MyD88),through interation between their C-tterminal toll0IL-1 receptor(TIR) domains.This recruitment of MyD88 to toll/IL-1 receptor domains of TLR9 initiates a signaling pathway that sequentially involves IL-1R-associated kinase(IRAK) family proteins and tumor necrosis factor-a receptor-associated factor(TRAF) 6 and TRAF3.
CpG-DNA can be recognized by TLR9 as its ligand,and subsequent produce proinflammatory cytokines,chemokines,and modulators in innate immune cells.Its beneficial effects on our immune system,as well as its therapeutic applications have been extensively studied.However,excenssive CpG DNA will induce a severe acute liver injury in a sequence-specific manner and subsequent shock-mediated death in mice treated with the hepatocyte-specifice transcription inhibitor D-GalN.
The present study attempts to address questions of whether bicyclol protect mice from CpG DNA-induced hepatitis and its possible mechanism.
We pretreat mice with bicyclol before CpG-ODN,and then measured alanine aminotransferase(ALT) levels in plasma,inflammatory infiltration and hepatocyte necrosis in liver.Potential therapeutic mechanisms were elucidated further by measuring several inflammatory mediators,chemotokines,TLR9 and signal transduction.Mice pretreated with bicyclol exhibited much less incresase ALT levels in plasma,reduced inflammatory infiltration and hepatocyte necrosis in liver compared with control mice pretreated with vehicle solutions.We further investigated the mechanisms of the protective effects of bicyclol.In bicyclol-pretreated mice,we found abrogated tumor necrosisi factor(TNF)-α,interferon(IFN)-γ,and interferon 18 at both serum and liver tissue.At the same time,the concentratin of MCP-1,MIP-1αand Rantes in plasma as well as in liver tissue were down-regulated in these mice.Moreover, Toll-like receptor 9 expression,p-NF-κB-p65 and p-p38 MAPK,pErk1/2 expressions in liver were decrease significantly.Therefore,bicyclol is capable of regulating immune-mediated liver injury in vivo.The protective effect depended on its suppressive effect on the production of important inflammatory medicators and TLR9 and its associated signal transductor.
Conclusion:Our study shows that bicyclol can alleviate liver injury induced by CpG-ODN.The suppressant effect was associated with inhibition of several inflammatory medicators,including TNF-α,IFN-γ,IL-18 and chemokines.
2.Inhibit effect and its mechanism of bicyclol on the production of chemokines and cytokines induced by CpG-OND in L02 cell line
Bacterial DNA and synthetic oligodeoxynucleotides(ODN) containing unmethylated CpG motifs stimulate the cells of the innate immune system trough a specifice receptor called Toll-like receptor-9(TLR9).
Here we report on the potential molecular mechanism of anti-inflammation induced by Bicyclol in L02 cells.The treatment of Bicyclol reduced the TLR9 ligand CpG-ODN induced the protein levels of chemokine(MCP-1,MIP-1α,Rantes ) and1 inflammation cytokines(TNF-α,IL-18),and weaken the release of CKs in a dose-dependent manner,suggesting Bicyclol impaired the onset of TLR9-mediated inflammation.
Through ELISA,the activity of p65-NF-κB and p38-MAPK was found to be attenuated after Bicyclol treatment.
Furthermore,the expression of phosphated NF-κB-p65 and the p38-MAPK,Erk1/2 were significantly altered by Bicyclol treatment,as demonstrated in western analysis.
All the above observations suggest that Bicyclol reduce TLR9 ligand-induced inflammation in L02 cells probably through suppressing the NF-κB and MAPK pathway.
Our results show for the first time that bicyclol exerts a protective effect on CpG-ODN/D-GalN induced hepatitis,with the evidence of a remarkable decrease of plasma level of alanine transaminase(ALT) 8-24 hours after injection and simulataneous amend of infiltration of the liver with neutrophils,macrophages and T tells,necrosis of the hepatocytes.The mechanism of its protective effect is possibly through suppression of inflammatory medicators and inhititing hepatocyte inflammation.Thus,bicyclol might be used to treat T-cell-mediated liver injury,such as autoimmune hepatitis, alcoholic hepatitis and chronic viral hepatitis.
双环醇(6-甲氧羰基-6'-羟甲基-2,3,2',3'-二亚甲基二氧基-4,4'-二甲氧基联苯)由中国医学科学院药物研究所刘耕陶院士和张纯贞教授合作的科研小组历经15年艰辛研制成功,该药降低转氨酶作用显著,对肝细胞具有较好的保护作用,并具有抗肝纤维化的作用,长期使用无明显不良反应。双环醇的问世为病毒性肝炎的治疗提供了一种新的安全、有效的辅助治疗药物,其药理基础和作用机制均值得继续深入研究。迄今为止,已有大量动物实验证明,双环醇对四氯化碳(CCl_4)、D-氨基半乳糖、对乙酰氨基酚、脂多糖(LPS)和刀豆蛋白A(ConA)等化学物质诱导的肝损伤均有保护作用,作用机制涉及抑制氧化和免疫损伤、细胞凋亡和细胞膜稳定等。但尚缺乏双环醇对病毒感染造成的肝脏炎症的保护作用及其机制的研究。
近年来关于病原体相关分子模式(Pathogen-associated molecular patterns,PAMPs)的研究进展表明,激活高等动物天然免疫应答的PAMPs广泛存在于病原体细胞表面,识别PAMPs是以模式识别受体(Pattern recognition receptors,PPRs),Toll样受体(Toll-like receptors,TLRs)介导的。细菌和病毒的DNA作为一种PAMPs能被机体识别并激发免疫应答,是因为其基因组中的一段以非甲基化CpG二核苷酸为核心的高保守序列,即CpG基序(CpG motif)。机体免疫系统通过TLR9(Toll-like receptor 9)特异识别细菌和病毒DNA中的CpG基序并形成受体复合物后,通过髓性分化因子88(myeloid differentiation factor 88,MyD 88)依赖途径,激活NF-κB(nuclear factor-κB)通路和应激酶通路等信号转导通路,促进机体产生Th1型细胞应答和分泌炎症因子,当炎症因子过度释放时,则造成宿主的炎症或损伤。研究证实人工合成的含一个或数个非甲基化CpG基序的寡聚脱氧核糖核酸(CpGoligodeoxynucleotides,CpG-ODNs),也具有和细菌及病毒DNA中CpG基序一样的免疫刺激效应。因此,CpG-ODNs可用以模拟细菌和病毒等微生物病原侵入机体所引发的免疫反应状态,构建相应的疾病模型。
目前已有研究小组构建了CpG-DNA/LPS以及CpG-DNA/D-GalN诱导的小鼠肝损伤模型,为我们进一步研究病毒感染后的肝脏炎症免疫病理提供了可能的模型。本研究中,我们用CpG-ODN/D-GalN造成小鼠肝损伤,模拟小鼠感染DNA病毒后所引起的肝脏炎症反应,来研究双环醇的保护作用和机制。根据CpG-ODN的免疫活性具有种属特异性的特征,第一部分研究中,我们以对小鼠具有最佳免疫效果的CpG1826构建小鼠肝损伤模型;第二部分研究中,则以对人类最具免疫效应的CpG2006模拟病毒刺激人正常细胞株L02细胞,从整体动物和离体细胞两个水平研究双环醇对CpG-ODN造成的免疫性炎症的保护作用,及其对TLR9介导的信号通路分子的活化和细胞因子分泌的作用。
1.双环醇对CpG-ODN/D-GalN诱导的小鼠肝损伤的保护作用及其机制
目的:用CpG-ODN诱导D-GalN致敏的小鼠肝脏炎症,研究双环醇的保护作用及可能的机制。
方法:BALB/C小鼠随机分组,每组8只。第1至5天每天一次给小鼠灌胃300mg/kg和100mg/kg双环醇或溶剂;第5天给药后2小时由尾静脉注射CpG-ODN(1826)20μg/D-GalN20mg/只,模型组仅在第5天尾静脉注射CpG-ODN(1826)20μg/D-GalN20mg/只。12小时后处死小鼠并留取标本。光镜观察肝脏损伤的程度;生物化学法测定血清中ALT;ELISA法测定血清及肝脏组织匀浆中细胞因子TNF-α,IL-18和IFN-γ及趋化因子MCP-1,MIP-lα和RANTES的水平;免疫组化法检测肝脏中TLR9表达;Westernblot方法测定NF-κB及MAPKs信号途径相关分子,包括p65,p38和Erk1/2的变化。
结果:模型组小鼠血清ALT为557.33±69.51(U/L),比正常组小鼠ALT高6倍;双环醇100mg/kg和300mg/kg组的ALT分别为227.67±55.59和138.45±22.52(U/L),与模型组相比分别降低59.1%和75.2%;肝脏组织病理切片结果显示,双环醇能减少肝脏炎症细胞浸润及肝细胞的溶解性坏死,减轻肝脏的损伤程度;双环醇100mg/kg和300mg/kg组血清中的细胞因子TNF-α、IL-18和IFN-γ的水平和趋化因子MCP-1、MIP-1α和Rantes的水平均显著低于模型组,且具有剂量相关性。其中血清中TNF-α降低35.6%和72.4%;IL-18降低21.80%和47.4%;IFN-γ降低30.90%和63.3%,MCP-1降低30.5%和72.6%,MIP-1α降低28.7%和38.2%,Rantes降低25.4%和64.5%,都具有显著差异;同时,双环醇对小鼠肝脏组织中的细胞因子和趋化因子也有类似的作用;免疫组化结果显示,双环醇处理组小鼠肝脏内TLR9表达明显少于模型组;Western blot结果则表明,双环醇组p-NF-κB-p65、p-MAPK-p38和p-MAPK-Erkl/2的表达明显低于模型组。
结论:双环醇能够抑制CpG-ODN/D-GalN诱导的小鼠肝脏炎症,其主要机制可能是通过参与小鼠的免疫调节作用,抑制炎症因子TNF-α,IL-18,IFN-γ的过量表达,同时抑制TLR9介导的信号通路中的有关分子的活化,通过参与小鼠免疫调节,从多方面对CpG-ODN诱导的小鼠肝损伤起到保护作用。
2.双环醇对CpG-DNA诱导的L02细胞TLR9表达及炎症、趋化因子分泌的抑制作用及其分子机制
研究表明,炎症发生时,肝实质细胞也参与了机体的免疫反应,能对炎症信号作出反应,分泌一些炎症细胞因子和趋化因子,并通过作用于临近的肝细胞、枯否氏细胞、内皮细胞和浸润到肝脏的白细胞等发起、扩大和改变炎症反应。CpG-ODN可直接作用于肝实质细胞,上调肝细胞上的粘附分子和共刺激分子,从而使肝细胞具有了类似于抗原递呈细胞的功能,从而打破了机体的免疫耐受,对肝脏造成炎症性损伤。因此,本部分研究中,我们以正常人肝细胞株L02作为研究对象,研究双环醇对CpG-ODN刺激后的L02细胞分泌细胞因子、趋化因子及TLR9表达等的影响。
目的:以CpG2006模拟双链DNA病毒刺激L02细胞并观察双环醇对L02细胞分泌炎症、趋化因子,以及对细胞内TLR9表达的影响,研究双环醇对与炎症作用相关的分子的调节作用和机制。
方法:用不同浓度双环醇(0.01,0.1,0.5mM)与L02细胞温孵2小时后,加入浓度为10μg/ml CpG-ODN2006,继续培养18小时,模型组仅加入10μg/mlCpG-ODN2006。用ELISA法测定培养上清中TNF-α和IL-18及趋化因子MCP-1,RANTES和MIP-1α等水平;Western blot法和流式细胞术测定L02细胞内TLR9的表达;Western blot法测定细胞内p-NF-κB p65、p -p38-MAPK,pErk1/2-MAPK的变化。
结果:双环醇能够剂量依赖性地抑制CpG-ODN诱导的L02细胞趋化因子的释放和TNF-α等细胞因子的分泌,其中双环醇0.5mM组和模型组相比,TNF-α、IL-18、MCP-1、MIP-1α和Rantes分别降低77.9%,88.7%,74.6%,63.3%和64.0%。Werstern blot和流式细胞术结果一致表明,双环醇0.5mM和0.1mM能够下调L02细胞内经ODN诱导表达的TLR9,同时,还能抑制相关NF-κB通路蛋白p65和MAPK通路相关蛋白p38及ERK1/2的磷酸化。
结论:双环醇能明显抑制CpG-ODN诱导的人肝细胞株L02炎症因子和趋化因子的释放与分泌,并且抑制L02细胞内TLR9的表达及相关NF-κB和MAPK信号传导途径分子的磷酸化活性。
综上,本课题首次研究了双环醇对CpG-ODN诱导的小鼠肝损伤的保护作用,并从整体动物水平和离体细胞水平研究了双环醇对肝细胞的保护作用机制。结果表明,双环醇能显著降低CpG-ODN诱导上升的小鼠血清转氨酶并改善肝脏病理情况。其机制可能与双环醇既参与机体的免疫调节,又对肝细胞有直接的保护作用有关。双环醇在体内能抑制小鼠血清和肝组织中炎症因子(TNF-α,IL-18,IFN-γ)和趋化因子MCP-1,MIP-1α,和RANTES的水平;同时也能直接抑制体外培养的L02细胞分泌这些因子。同时,双环醇还能下调L02细胞内TLR9的表达及其信号途径所涉及的信号转导分子如NF-κB-p65,MAPK-p38和ERK1/2的活化。因此,双环醇可以从多途径减轻CpG-ODN对肝脏造成的损伤,从而达到治疗肝炎的效果。这些研究结果也提示,双环醇抗肝细胞炎症的作用有免疫学机制的介入,为解释双环醇在临床上治疗肝炎的分子机制提供了更多的的理论依据。
Chronic viral hepatitis is a worldwide disease,in particular,the incidence of chronic viral hepatitis B(CHB) in China is the highest in the world.Around 25%to 40% of the CHB population die from hepatocirrhosis or liver cancer leaded by hepatitis. Although many drugs have been used in the treatment of CHB and chronic viral hepatitis C patients,among them,interferon -2αand Lamivudine are widely used. However,there is a high rebound rate of HBV-DNA after withdrawal of lamivudine, and the side effects of interferon-2αand Lamivudine are unacceptable.Therefore,it is an urgent need to develop effective and safe new drugs to treat chronic viral hepatitis in China.
Virus of hepatitis B does not damage hepatocyte directly.However,T cell-mediated immune responses play an essential role in hepatocellular injury induced by autoimmune hepatitis,viral infection,and hepatotoxines.When effection happened, chemokines and cytokines were produced at the sites of inflammation and play an essential role in the recruitment of particular cell types that infiltrate and participate in the pathologic lesions,then hepatitis injury develops with infiltratin and/or proliferation of T cells and macrophages.Therefore,to modulate and inhibit inflammation in liver is one of the most important therapy strategies of treatment of CHB.
Bicyclol,4,4'-dimethoxy-5,6,5',6'-bis(dimethylene-dioxy)-2-hydroxymethyl-2'-m ethoxy carbonyl biphenyl) is a novel synthetic anti-hepatitis drug for the treatment of chronic hepatitis B patients in China.Numerous reports have shown that Bicyclol has protective effect against various forms of acute and chronic experimental liver injury, such as liver injury induced by carbon tetrachloride,acetaminophen,D-galactosamine, concanavalin and alcohol.Bicyclol excerts its anti-inflammatory effect thgough reflecting the function of neutrophils,monocytes or macrophages,It has been reported that the hepatoprotective mechanisms of Bicyclol involve the clearance of reactive oxygen species,regulation of cytokine secretion,and inhitition of apotosis induced by immunological injury,etc.
The purpose of the present study was to determine whether bicyclol had protective effect on liver injury induced by CpG-ODN,a rodent model represents early pathological changes in viral hepatitis,and investigate related mechanisms on cytokine expression,TLR9 expression and NF-κB& MAPK signal pathway.The results in vivo and in vitro demonstrated that oral administration of bicyclol significantly ameliorated liver injury by reducing the production of inflammatory cytokines and chemokines,and inhititing TLR9 and NF-κB& MAPK signal transduction caused by CpG-ODN.
1.Bicyelol protects mice from CpG-ODN -induced hepatitis and its mechanism
The innate immune cells recognize conserved molecular patterns present in microbes(pathogen-associated molecular patterns through a family of proteins known as toll-like receptors(TLRs) that function as pattern recognition receptors and are therby activated to exert various effector functions,including secretion of pro-inflammatory cytokines and mediators such as TNF-α,IL-6,IL-12,and nitric oxide.Production of inflammatory mediators and pro-inflammatory cytokines by innate immune cells is indispensable for the efficient control of growth and dissemination of invading pathogens.However,excessive and uncontrolled production of inflammatory medicators and pro-inflammatory cytokines caused by bacterial infection is potentially harmful to the host and may lead to sever systematic inflammatory complications.
Unmethylated CpG dinucleotides in particular sequence contexts(CpG motifs, GACGTT for murine and GTCGTT for human) in bacterial DNA are capable of activationg innate immune cells and are one of the well studied pathogen-associated molecular patterns.The ability of bacterial DNA to activate innate immunity can be mimicked by synthetic oligodexynucleotides containing the unmethylated CpG motif. This unmethylated CpG motif containing bacterial DNA and synthetic oligodeoxynucleotides(CpG DNA) are endocytosed and then recognized as a conserved molecular patern by a pattern recognition receptor TLR9 in an endosomal compartment of antigen-presenting cells in the vertebrate innate immune system.
Upon recognition of CpG DNA,TLR recruits the adaptor molecule,myeloid differentiation factor 88(MyD88),through interation between their C-tterminal toll0IL-1 receptor(TIR) domains.This recruitment of MyD88 to toll/IL-1 receptor domains of TLR9 initiates a signaling pathway that sequentially involves IL-1R-associated kinase(IRAK) family proteins and tumor necrosis factor-a receptor-associated factor(TRAF) 6 and TRAF3.
CpG-DNA can be recognized by TLR9 as its ligand,and subsequent produce proinflammatory cytokines,chemokines,and modulators in innate immune cells.Its beneficial effects on our immune system,as well as its therapeutic applications have been extensively studied.However,excenssive CpG DNA will induce a severe acute liver injury in a sequence-specific manner and subsequent shock-mediated death in mice treated with the hepatocyte-specifice transcription inhibitor D-GalN.
The present study attempts to address questions of whether bicyclol protect mice from CpG DNA-induced hepatitis and its possible mechanism.
We pretreat mice with bicyclol before CpG-ODN,and then measured alanine aminotransferase(ALT) levels in plasma,inflammatory infiltration and hepatocyte necrosis in liver.Potential therapeutic mechanisms were elucidated further by measuring several inflammatory mediators,chemotokines,TLR9 and signal transduction.Mice pretreated with bicyclol exhibited much less incresase ALT levels in plasma,reduced inflammatory infiltration and hepatocyte necrosis in liver compared with control mice pretreated with vehicle solutions.We further investigated the mechanisms of the protective effects of bicyclol.In bicyclol-pretreated mice,we found abrogated tumor necrosisi factor(TNF)-α,interferon(IFN)-γ,and interferon 18 at both serum and liver tissue.At the same time,the concentratin of MCP-1,MIP-1αand Rantes in plasma as well as in liver tissue were down-regulated in these mice.Moreover, Toll-like receptor 9 expression,p-NF-κB-p65 and p-p38 MAPK,pErk1/2 expressions in liver were decrease significantly.Therefore,bicyclol is capable of regulating immune-mediated liver injury in vivo.The protective effect depended on its suppressive effect on the production of important inflammatory medicators and TLR9 and its associated signal transductor.
Conclusion:Our study shows that bicyclol can alleviate liver injury induced by CpG-ODN.The suppressant effect was associated with inhibition of several inflammatory medicators,including TNF-α,IFN-γ,IL-18 and chemokines.
2.Inhibit effect and its mechanism of bicyclol on the production of chemokines and cytokines induced by CpG-OND in L02 cell line
Bacterial DNA and synthetic oligodeoxynucleotides(ODN) containing unmethylated CpG motifs stimulate the cells of the innate immune system trough a specifice receptor called Toll-like receptor-9(TLR9).
Here we report on the potential molecular mechanism of anti-inflammation induced by Bicyclol in L02 cells.The treatment of Bicyclol reduced the TLR9 ligand CpG-ODN induced the protein levels of chemokine(MCP-1,MIP-1α,Rantes ) and1 inflammation cytokines(TNF-α,IL-18),and weaken the release of CKs in a dose-dependent manner,suggesting Bicyclol impaired the onset of TLR9-mediated inflammation.
Through ELISA,the activity of p65-NF-κB and p38-MAPK was found to be attenuated after Bicyclol treatment.
Furthermore,the expression of phosphated NF-κB-p65 and the p38-MAPK,Erk1/2 were significantly altered by Bicyclol treatment,as demonstrated in western analysis.
All the above observations suggest that Bicyclol reduce TLR9 ligand-induced inflammation in L02 cells probably through suppressing the NF-κB and MAPK pathway.
Our results show for the first time that bicyclol exerts a protective effect on CpG-ODN/D-GalN induced hepatitis,with the evidence of a remarkable decrease of plasma level of alanine transaminase(ALT) 8-24 hours after injection and simulataneous amend of infiltration of the liver with neutrophils,macrophages and T tells,necrosis of the hepatocytes.The mechanism of its protective effect is possibly through suppression of inflammatory medicators and inhititing hepatocyte inflammation.Thus,bicyclol might be used to treat T-cell-mediated liver injury,such as autoimmune hepatitis, alcoholic hepatitis and chronic viral hepatitis.
引文
[1]Rico MA,Quiroga JA,Subir(?) D,et al.Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.Hepatology.2001;33:295-300.
[2]Boni C,Penna A,Bertoletti A,et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.J Clin Invest.1998;102:968-75.
[3]Milich DR.Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.J Viral Hepat.1997;4 Suppl 2:48-59.
[4]Tiegs G,Hentschel J,and Wendel A.A T cell-dependent experimental liver injury in mice inducible by concanavalin A.J Clin Invest.1992;90:196-203.
[5]Cantner F,Leist M,Lohse AW,et al.Concanavalin A induced T-cell-mediated hepatic injury in mice:the role of tumor necrosis factor.Hepatology.1995;21:190-8.
[6]Sabine K,Florian G,Gerald K,et al.Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by Concanavlin A.Gastroenterology.1996;111:462-71.
[7]Aderem A,and Ulevitch RJ.Tolll-like receptors in the induction of the innate immune response.Nature.2000;406:782-87.
[8]Hemmi H,Takeuchi O,Kawai T,et al.A toll-like receptor recognizes bacterial DNA,Nature.2000,408:740-745.
[9]Liu X,Xu Q,Chen W,et al.Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of nonmethylated CpG DNA.Oncology Reports.2009;21:941-47.
[10]Hartmann G.,Weeratna RD,Ballas ZK,et al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol.2000;164:1617-24.
[11]Krieg AM.CpG motifs in bacterial DNA and their immune effects.Annu Rev Immunol.2002;20:709-60.,
[12]Rutz M,Metzger J,Gellert T,et al.Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner.Eur J.Immunol.2004;34:2541-50.
[13]Bauer S,Kirschning CJ,Hacker H,et al.Human TLR9 confers responsiveness to bacterial DNA via secies-specific CpG motif recognition.Proc.Natl.Acad.Sci.U.S.A.2001;98:9237-42.
[14]Latz E,Schoenemeyer A,Visintin A,et al.TLR9 signals after translocating from the ER to CpG DNA in the lysosome.Nat.Immunol.2004;5:190-98.
[15]Comelie S,Hoebeke J,Schacht AM,et al.Direct evidence that Toll-like receptor 9)TLR9) functionally binds plasmid DNA by specific CpG motifs recognition.J.Biol.Chem.2004;279:15124-29
[16]Krieg AM,Yi AK,Schorr J,et al.The role of CpG dinucleotides in DNA vaccines.Trends Microbiol.1998;6:23-7.
[17]Klinman DM.Immunotherapeutic uses of CpG oligodeoxynucleotides.Nat.Rev.Immunol.2004;4:249-59.
[18]Juffermans NP,Leemans JC,Florquin S,et al.CpG oligodeoxynucleotides enhance host defense during murine tuberculosis.Infect.Imun.2002;70:147-52.
[19]Jorg V.and Arthur M.Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.Advanced Drug Delivery Review.2009;61:195-204
[20]McHutchison JG,Bacon BR,Gordon SC,et al.Relationships of HCV RNA responses to CpG 10101,a TLR9 agonist:pharmacodynamics & patient characteristics.AAASID.2005;abstract.
[21]Krie AM.Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides.Curr Oncol Rep.2004;6:88-95.
[22]Rankin R,Pontarollo R,Gomis S,et al.CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1glycoprotein D.Vaccine.2002;20:3014-22.
[23]Wernette CM,Smith BF,Barksdale ZL,et al.CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation.Vet Immunol Immunopathol.2002;84:223-36.
[24]Sven Klaschik,Debra Tross,and Nennis MK.Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.J Leukoc Biol.2009;Jan 29.Epub ahead of print.
[25]Kreig M,Vollmer J.Toll-like receptors 7,8 and 9:linking innate immunity to autoimmunity.Immunol.Rev.2007;220:251-69.
[26]Chaturvedi A,Dorward D,Pierce Sk.The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens.Immunity.2008;28:799-809.
[27]Sacher T,Knolle P,Nichteriein T,et al.CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol.2002;32:3628-37.
[28]Kim YI,Park JE,Martinez-Hernandez A,et al.CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1receptor-associated kinases.J Biol Chem.2008;283:15258-70.
[29]Slotta JE,Scheuer C,Menger M,et al.Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury,but provide a late window for protection against endotoxin-mediated liver damage.J Hepatol.2006;44:576-85.
[30]Yi AK,Yoon H,Park J,et al.CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice:the mitochondrial apoptotic pathway-dependent death of hepatocytes.J Biol Chem,2006.281:15001-12.
[31]Liu GT,Li Y,Wei HL,et al.Mechanism of protective action of bicyclol against CCl-induced liver injury in mice.Liver Int.2005;25:872-9.
[32]Li Y,Dai GW,Li Y,Liu GT.Effect of bicyclol on acetaminophen-induced hepatotoxicity:energetic metabolism and mitochondrial injury in acetaminophenintoxicated mice.Yao Xue Xue Bao.2001;36:723-6.
[33]Wang H and Li Y.Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol.2006;534:194-201.
[34]Zhao D and Liu GT.Protective effect of bicyclol on concanavalin A-induced liver nuclear DNA injury in mice.Zhonghua Yi Xue Za Zhi.2001;81:844-8.
[35]Li M and Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004;10:1775-9.
[36]Yu YN,Guo J,Li Y,et al.Effect of bicyclol on gene expression profiles in mice with liver injury induced by concanavalin A.Yao xue xue bao.2008;43:596-600.
[37]Liu GT.Bicyclol:a novel drug fro treating chronic viral hepatitis B and C.Med Chem.2009;5:29-43.
[38]Bao XQ,Liu GT.Induction of heat shock protein 27 and 70 overexpression by bicyclol attenuates concanavalin A-induced liver injury through suppression of NF-κB in mice.Mol pharmacol.2009;Epub ahead of print.
[39]Bao XQ,Liu GT.Bicyclol:a novel antihepatitis drug with hepatic heat shock protein 27/70-induceing activity and cytoprotective effects in mice.Cell stress chaperones.2008;13:347-55.
[40]Yu Z,Jiang H,Kan Q,et al.Dynamically analyzing on the anti-virus and hepatoprotective effects of bicyelol.China pharmaceuticals.2003;12:27-8.
[41]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei Med J.2002;43:657-64.
[42]Rico MA,Quiroga JA,Subir(?) D,et al.Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.Hepatology.2001;33:295-300.
[43]Boni C,Bertoletti A,Penna A,et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.J Clin Invest.1998;102:968-75.
[44]Milich DR.Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.J Viral Hepat.1997;4 Suppl 2:48-59.
[45]Muhanna N,Doron S,Wald O,et al.Activation of hepatic stellate cells after phagocytosis of lymphocytes:A novel pathway of fibrogenesis.Hepatology.200;48:963-77.
[46]Miyaaki H,Zhou H,Ichikawa T,et al.Study of liver-targeted regulatory T cells in hepatitis B and C virus in chronically infected patients.Liver Int,2008.Pub ahead of print.
[47]Zhang HH,Guo F,Fei R,et al.Inhibition of CD4+ CD25+ regulatory T cells in chronic hepatitis B patients.Zhonghua Yi Xue Za Zhi.2008;88:511-5.
[48]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei M ed J.2002;43:657-64.
[49]PromratK,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[50]ApolinarioA,MajanoPL,Alvarez-PtrezE,etal.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[51]Puren AJ,Fantozzi G,Dinarello CA.Gene expression,synthesis,and secretion of interleukin-18 and interleukin-beta are differentially regulated in homan blood mononuclear cells and mouse spleen cells.Proc Natl Acad Sci USA.1999;96:2256-61.
[52]Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18 biological properties and clinical implications.Eur Cytokine Netw.2000;11:15-25.
[53]Tsutsui H,Matsui K,Okamura H,et al.Pathophysiological roles of Interleukin-18 in inflammatory liver disease.Immunological Review.2000;174:192-209.
[54]Dinarello CA.Interleukin-18,a proinflammatory cytokine.Env Cytokine Netw.2000;1:483-86.
[55]Promrat K,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[56]ApolinarioA,MajanoPL,Alvarez-Ptrez E,et al.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[57]Duan ZP,Zhao XY,Huang DZ,et al.RANTES gene single nucleotide polymorphisms an d expression in patients with chr onic hepatitis B virus infection.Chin Med J(Engl).2005;118:909-14.
[58]Wagner H.Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity.Curr Opin M icrobiol.2002;5:62-69.
[59]Ashkar AA,Rosenthal K L.Toll-like receptor9,CpG DNA and innate immunity.Curr Mol Med.2002;2:545-56.
[60]Hemmi H,TakeuchiO,Kawai T,et al.A Toll-like receptor recognizes bacterial DNA.Nature.2000;408:740-745.
[61]Takeshita F,Gursel I,Ishii K J,et al.Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.Semin Immunol.2004;16:17-22.
[62]Verthelyi D,Zeuner RA.Differential signaling by CpG DNA in DC and B cells:not just TLR9.Trends Immuno.2003;21:519-22.
[63]Takeshita F,Leifer CA,Gursel I,et al.Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immnuno.2001;167:3555-8.
[64]Lee S,Hong J,Choi S,et al.CpG oligodeoxynucleotides induce expression of proinflammartory cytokines and chemokines in astrocytes:the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-κB activation.Journal of Neuroimmunology.2004;153:50-63.
[65]Shubing L,David JG,Angela MG,et al.Role of toll-like receptors in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with lipopolysaccharide.Infection and immunity.2002;70:3433-42.
[66]Hacher H,Vabulas RM,Takeuchi O,et al.Immune cell activation by bacterial CpG-DNA through myeroid differentiation marker 88 and tumor necrosisi factor receptor-associated factor(TRAF)6.J.Exp.Med.2000;192:595-600.
[67]Aderem A,Ulevitch RJ.Toll-like receptors in the induction of the innate immune response.Nature.2000;406:782-87.
[68]Elsharkawy AM,Mann DA.Nuclear factor-kappaB and the hepatic inflamm ation-fibrosis-cancer axis.Hepatology.2004;6:590-7.
[69]Christman JW,Lan caster LH,Blackwell TS.Nuclear factor kappa B:a pivotal role in the systemic inflammatory response syndrome and new target for therapy.Intensive Care Med.1998;24:1131-8.
[70]Shibolet O and D.K.Podolsky.TLRs in the Gut.Ⅳ.Negative regulation of Toll-like receptors and intestinal homeostasis:addition by subtraction.Am J Physiol Gastrointest Liver Physiol.2007;292:1469-73.
[71]Saklatvala J.Inflammatory signaling in cartilage:MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis.Curr Drug Targets.2007;8:305-13.
[1]Krieg AM,Yi AK,Matson S,et al.CpG motifs in bacterial DNA trigger direct B-cell activation.Nature.1995;374:546-549.
[2]Krieg AM,Yi AK,Schorr J,et al.The role of CpG dinucleotides in DNA vaccines.Trends Microbiol.1998;6:23-7.
[3]Hartmann G,Weeratna RD,Ballas ZK,et al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol.2000;164:1617-24.
[4]Medzhitov R,Janeway CA Jr.Innate immunity:impact on the adaptive immune response.Curr Opin Immunol.1997;9:4-9.
[5]Moser B,Loetscher P.Lymphocyte traffic control by chemokines.Nat Immunol.2001;2:123-8.
[6]Takeda K,Kaisho T,and Akira S.Toll-like receptors.Annu Rev Immunol.2003.21:335-76.
[7]Akira S and Takeda K.Toll-like receptor signalling.Nat Rev Immunol.2004;4:499-511.
[8]Xu N,Yao H,Sun Z,et al.Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma.Acta Pharmacol Sin.2008;29:239-44.
[9]Moser B and Loetscher p.Lymphocyte traffic control by chemokines.Nat.Immunol.2001;2:123-128.
[10]Krieg AM,Harmann G and Yi AK.Mechanism of action of CpG DNA.In Wagner,H.(Ed.) Current Topics in microbiology and immunology,vol.247.Springer,Berlin 2000;1-21
[11]Liu GT.Bicyclol:a novel drug for treating chronic viral hepatitis B and C.Med Chem.2009;5:29-43.
[12]Liu GT,Li Y,Wei HE,et al.Mechanism of protective action of bicyclol against CCl-induced liver injury in mice.Liver Int.2005;25:872-9.
[13]Li Y,Dai GW,Li Y,et al.Effect of bicyclol on acetaminophen-induced hepatotoxicity:energetic metabolism and mitochondrial injury in acetaminophen-intoxicated mice.Yao Xue Xue Bao.2001;36:723-6.
[14]Zhao D and Liu GT.Protective effect of bicyclol on concanavalin A-induced liver nuclear DNA injury in mice.Zhonghua Yi Xue Za Zhi.2001;81:844-8.
[15]Li M.and Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004;10:1775-9.
[16]Wang H and Li Y.Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol 2006;534:194-201.
[17]Bao XQ and Liu GT.Bicyclol:a novel antihepatitis drug with hepatic heat shock protein 27/70-inducing activity and cytoprotective effects in mice.Cell Stress Chaperones.2008;13:347-55.
[18]Bao XQ and Liu GT.Induction of heat shock protein 27 and 70 overexpression by bicyclol attenuates concanavalin A-induced liver injury through suppression of NF-{kappa}B in mice.Mol Pharmacol 2009;[Epub ahead of print]
[19]Wanless IR.Physioanatomic considerations.In:Schiff ER,Sorrell MF,Maddrey WC,eds.Schiff's Diseases of the Liver,8th edn.Philadelphia,PA:Lippincott-Raven Publishers,1998;16.
[20]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei Med J.2002;43:657-64.
[21]Rowell DL,Eckmann L,Dwinell MB,et al.Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion.Am J Physiol.1997;273:G322-32.
[22]Wegenka UM,Buschmann J,L(u|¨)tticken C,et al.Acute-phase response factor,a nuclear factor binding to acute-phase response elements,is rapidly activated by interleukin-6 at the posttranslational level.Mol Cell Biol.1993;13:276-88.
[23]Moshage H.Cytokines and the hepatic acute phase response.J Pathol.1997.181:257-66.
[24]Loomba R and Liang TJ.Treatment of chronic hepatitis B.Antivir Ther.2007;12 Suppl 3:H33-41.
[25]Gutierrez-Reyes G,Gutierrez-Ruiz MC,and Kershenobich D.Liver fibrosis and chronic viral hepatitis.Arch Med Res.2007;38:644-51.
[26]Promrat K,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[27]Apolinario A,Majano PL,Alvarez-P(?)rez E,et al.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[28]Duan ZP,Zhao XY,Huang DZ,et al.RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection.Chin Med J(Engl).2005;118:909-14.
[29]Masihi KN.Novel concepts for anti-infective activity of cytokines,chemokines and diverse agents.Recent Pat Antiinfect Drug Discov.2006;1:147-56.
[30]Cheong JY,Cho SW,Choi JY,et al.RANTES,MCP-1,CCR2,CCR5,CXCR1and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection.results from a large scale single ethnic population.J Korean Med Sci.2007;22:529-35.
[31]Tilg H,Kaser A,and Moschen AR.How to modulate inflammatory cytokines in liver diseases.Liver Int.2006;26:1029-39.
[32]Zou Z,Li B,Xu D,et al.Imbalanced Intrahepatic Cytokine Expression of Interferon-gamma,Tumor Necrosis Factor-alpha,and Interleukin-10 in Patients With Acute-on-Chronic Liver Failure Associated With Hepatitis B Virus Infection.J Clin Gastroenterol.2009;43:182-90
[33]Falasca K,Ucciferri C,Dalessandro M,et al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C.Ann Clin Lab Sci.2006;36:144-50.
[34]Lebel-Binay S,Berger A,Zinzindohou(?) F,et al.Interleukin-18:biological properties and clinical implications.Eur Cytokine Netw.2000;11:15-26.
[35]Tsutsui H.Matsui K,Okamura H,et al.Pathophysiological roles of interleukin-18 in inflammatory liver diseases.Immunol Rev.2000;174:192-209.
[36]Dinarello CA,Interleukin-18,a proinflammatory cytokine.Eur Cytokine Netw.2000;11:483-6.
[37]Yi AK,Yoon H,Park JE,et al.CpG DNA-mediated induction of acute liver injury in D-Galactosamine-sensitized mice.The Journal of biological chemistry.2006;281:15001-12.
[38]Kazumichi A,Hiromasa O,Hiroko K,et al.Role of CpG ODN in concanavalin A-induced hepatitis in mice.Fukushima J.Med.Sci..2005;51:41-9.
[39]Lim EJ,Lee SH,Lee JG,et al.Toll-like receptor 9 dependent activation of MAPK and NF-κB is required for the CpG ODN-induced matrix metalloproteinase-9 expression.Experimental and molecular medicine.2007,39:239-46.
[40]Lim E J,Lee SH,Lee JG,et al.Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.FEBS Lett.2006;580:4533-8.
[41]Osawa Y,Iho S,Takauji R,et al.Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells.The Journal of Immunology.2006,177:4841-52.
[42]Kawai T and Akira S.Signaling to NF-kappaB by Toll-like receptors.Trends Mol Med.2007;13:460-9.
[43]Yang K,Puel A,Zhang S,et al.Human TLR-7,-8,and-9-mediated induction of IFN-alpha/beta and-lambda is IRAK-4 dependent and redundant for protective immunity to viruses.Immunity.2005;23:465-78.
[1]刘耕陶.国家一类抗肝炎新药双环醇片.传染病信息,2002,15:3-4.
[2]Wang H,Li Y.Protective effect of bicyclol on actute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol,2006,534:194-201.
[3]李敏,刘耕陶.双环醇对脂多糖诱导巨噬细胞iNOs蛋白的表达和NF-κB 的抑制作用.中国药理学通报,2006,22:1438-43.
[4]刘耕陶,李敏,孙华,等.一类抗肝炎新药双环醇药理研究的新进展.中国药理通讯,2005,22:1-2.
[5]莫成林,李烨,李燕.双环醇对小鼠慢性酒精性肝损伤的保护作用.中华医学杂志,2005,85:3409-3413.
[6]Lu H,Li Y.Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats.Acta Pharmacol Sin.2002,23:942-945.
[7]陈燕琴,高同军,迟俭,等.双环醇片治疗抗结核药物性肝损害临床疗效和安全性分析.传染病信息,2005,18:188-189.
[8]Liu GT,Li Y,Wei HL,et al.Mechanism of protective action of bicyclol against CC14-induced liver injury in mice.Liver Int.2005,25:872-879.
[9]刘耕陶.双环醇的抗病毒与肝细胞保护作用及其作用机制.中国新药杂志,2001,10:325-327.
[10]赵冬梅,刘耕陶.双环醇对刀豆蛋白A所致小鼠肝细胞核DNA损伤的保护作用.中华医学 杂志,2001,81(14):844-848.
[11]Li M,Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004,10:1775-1779.
[12]李烨,戴国炜.双环醇对扑热息痛引起的小鼠肝脏能量代谢和线粒体功能障碍的影响.药学学报,2001,36:723-726.
[13]赵冬梅,刘耕陶.双环醇对乙酰氨基酚致小鼠肝线粒体损伤的保护作用.中国新药杂志,2002,11:536-540.
[14]Liu GT,Zheng CZ,Li Y,et al.Clinical and pharmacological study of bicyclol-a potential anti chronic viral hepatitis drug.Clin Med Sci J,1999;14:51-53.
[15]Yang XY,Zhou Q,Wu TX,et al.Bicyclol for chronic hepatitis C.Cochrane Database Syst Rev.2007,24:CD004994.
[16]余祖江,江河清,阚全程,等.双环醇抗病毒与保护肝细胞作用的动态观察和分析.中国药业,2003,12:27-28.
[17]Rehermann B,Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol,2005,5:215-218.
[18]吴兴柳,王鸿香,钟根钳.双环醇与拉米夫定联合治疗慢性乙型肝炎的临床疗效及对T细胞亚群的影响.中国医院用药评价与分析.2005,5:235-237.
[19]施斌斌,彭颉,温帆渊,等.百赛诺对慢性乙型肝炎患者细胞免疫应答的影响.第一军医大学学报,2005;25:706-708.
[20]Hu QW,Liu GT.Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action.Life Sci.,2006,79:606-612.
[21]韩春荣,何生松,徐标.双环醇对小鼠日本血吸虫病肝组织即早基因与TGF-β1表达的影响.中国病原生物学杂志,2006,1:434-437.
[22]易建华,李伟,曾令兰,罗端德.双环醇治疗慢性乙型病毒性肝炎肝纤维化及其作用机制.大连大学学报,2006,27:27-30.
[23]李烨,李燕,刘耕陶.双环醇对实验性肝纤维化的防护作用及分子机制.中华医学杂志,2004,84:2096-2010.
[24]鞠美华,李燕.双环醇在大鼠和人肝微粒体的代谢.药学学报,2005,40:111-116.
[25]Liu Q,Song Y,Zhou Y,et al.A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther,2006;5:1674-6.
[26]Zhu B,Liu GT,Wu RS,et al.Chemoprevention of bicyclol against hepatic preneoplastic lesions.Cancer Biol Ther,2006;5:1665-73.
[27]Hua Sun,Geng-Tao Liu.Chemopreventive effect of bicyclol on malignant transformation of WB-F344 rat liver epithelial cells and its effect on related signal transduction in vitro.Cancer Letters,2006,236:239-249.
[28]赵冬梅,孙韬,李燕.双环醇对大鼠肾脏缺血-再灌注损伤的保护作用.药学学报,2002,37:412-414.
[29]Pan SY,Dong H,Yu ZL,et al.Bicyclol,a synthetic dibenzocyclooctadiene derivative,decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.Pharm Pharmacol.2007,59:1657-1662.
[30]唐韬,李烨,李燕.双环醇对小鼠非酒精性肝病的保护作用和机制研究.中国药理通讯,2005,22:53-55.
[31]王建军,成军,刘妍,等.基因表达谱芯片筛选双环醇作用HepG2细胞后的差异表达基因.世界华人消化杂志,2004,12:1711-1714.
[32]郭江,纪冬,成军,等.双环醇下调细胞周期素B2基因启动子转录活性研究.胃肠病原菌学和肝病学杂志,2005,14:346-348.
[1]Bauer,S.,et al.,Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.Proc Natl Acad Sci U S A,2001.98(16):p.9237-42.
[2]Krieg,A.M.,et al.,CpG motifs in bacterial DNA trigger direct B-cell activation.Nature,1995.374(6522):p.546-9.
[3]Krieg,A.M.,CpG motifs in bacterial DNA and their immune effects.Annu Rev Immunol,2002.20:p.709-60.
[4]Yi,A.K.,et al.,Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.Int Immunol,2001.13(11):p.1391-404.
[5]Hacker,H.,et al.,Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells.Ernbo J,1999.18(24):p.6973-82.
[6]Hartmann,G.and A.M.Krieg,Mechanism and function of a newly identified CpG DNA motif in human primary B cells.J Immunol,2000.164(2):p.944-53.
[7]Sun,S.,et al.,Type Ⅰ interferon-mediated stimulation of T cells by CpG DNA.J Exp Med,1998.188(12):p.2335-42.
[8]Bendigs,S.,et al.,CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells.Eur J Immunol,1999.29(4):p. 1209-18.
[9]Takeshita,S.,et al.,CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression.Cell Immunol,2000.206(2):p.101-6.
[10]Sester,D.P.,et al.,Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.J Immunol,2000.165(8):p.4165-73.
[11]Yi,A.K.,et al.,Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production:central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Thl response.J Immunol,2002.168(9):p.4711-20.
[12]Hartmann,G.,et al.,CpG DNA:a potent signal for growth,activation,and maturation of human dendritic cells.Proc Natl Acad Sci U S A,1999.96(16):p.9305-10.
[13]Krieg,A.M.,et al.,The role of CpG dinucleotides in DNA vaccines.Trends Microbiol,1998.6(1):p.23-7.
[14]Hartmann,G.,et al.,Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol,2000.164(3):p.1617-24.
[15]Rankin,R.,et al.,CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D.Vaccine,2002.20(23-24):p.3014-22.
[16]Wernette,C.M.,et al.,CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation.Vet Immunol Immunopathol,2002.84(3-4):p.223-36.
[17]Sfondrini,L.,et al.,Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA.Faseb J,2002.16(13):p.1749-54.
[18]Wagner,H.Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity.Curr Opin Microbiol,2002,5(1):62-69.
[19]Ashkar,AA,and Rosenthal,K.L.,Toll-like receptor 9,CpG DNA and innate immunity.Curr Mol Med,2002,2(6):545-556.
[20]Heeg,K.,Zimmermann S.CpG DNA as a Th1 trigger.Int Arch Allergy Immunol,2000,121(2):87-97.
[21]Hemmi,H.,et al.,A Toll-like receptor recognizes bacterial DNA.Nature.2000;408(6813):740-5.
[22]Takeshita,F.,et al.,Cutting edge:role of toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immunol,2001,167(7):3555-3558.
[23]Chuang,T.H.,et al.,Toll-like receptor 9 mediates CpG-DNA signaling.J Leukoc Biol,2002,71(3):538-544.
[24]Hornung,V.,et al.,Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.J Immunol,2002.168(9):p.4531-7.
[25]Dalpke,A.H.,et al.,Immunostimulatory CpG-DNA activates murine microglia.J Immunol,2002.168(10):p.4854-63.
[26]Takeshita,F.,et al.,Cutting edge:Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immunol,2001.167(7):p.3555-8.
[27]Verthelyi,D.and R.A.Zeuner,Differential signaling by CpG DNA in DCs and B cells:not just TLR9.Trends Immunol,2003.24(10):p.519-22.
[28]Bauer,S.,et al.,Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition,in Proc Natl Acad Sci U S A.2001.p.9237-42.
[29]Wager H.Toll meets bacterial CpG DNA.Immunity,2001,14:499-502.
[30]Ahmad-Nejad,P.,et al.,Bacterial CpG DNA and lipopolsaccharides activate toll-like receptor at distinct cellular compartments.Eur J Immunol,2002,31(7):1958-1968.
[31]Leifer,C.,et al.,TLR9 is localized in the endoplasmic reticulum prior to stimulation.J Immunol,2004,173(2):1179-1183.
[32]Latz,E.,et al.,TLR9 signals after translocating from the ER to CpG DNA in the lysosome.Nat Immunol,2004.5(2):p.190-8.
[33]Krieg,A.M.,Now I know my CpGs.Trends Microbiol,2001.9(6):p.249-52.
[34]Medzhitov,R.,CpG DNA:security code for host defense.Nat Immunol,2001.2(1):p.15-6.
[35]Krieg,A.M.and H.Wagner,Causing a commotion in the blood:immunotherapy progresses from bacteria to bacterial DNA.Immunol Today,2000.21(10):p.521-6.
[36]Hacker,H.,et al.,Immunce cell activation by bacterial CpG DNA through myeloid differentiation factor(TRAF)6.J Exp Med,2000,192(4):595-699.
[37]Yi,A.K.,et al.,Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production:central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response.J Immunol,2002,16899:4711-20.
[38]Hoshino,K.,,et al.,Differential involvement of IFN-b in Toll-like receptor-stimulated dendritic cell activation.Int Immunol,2002,14(10):1225-31.
[39]Park,Y.,S.W.Lee,and Y.C.Sung,Cutting Edge:CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway.J Immunol,2002.168(1):p. 5-8.
[40]Cowdery,J.S.,et al.,Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides.J Immunol,1996.156(12):p.4570-5.
[41]Sparwasser,T.,et al.,Macrophages sense pathogens via DNA motifs:induction of tumor necrosis factor-alpha-mediated shock.Eur J Immunol,1997.27(7):p.1671-9.
[42]Sacher,T.,et al.,CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol,2002.32(12):p.3628-37.
[43]Yi,A.K.,et al.,CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice:the mitochondrial apoptotic pathwaydependent death of hepatocytes.J Biol Chem,2006.281(21):p.15001-12.
[44]Kim,Y.I.,et al.,CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1 receptor-associated kinases.J Biol Chem,2008.283(22):p.15258-70.
[45]Kaxumichi,A.,et al.,Role of CpG ODN in concanavalin A-induced hepatitis in mice.Fukushima J.Med.Sci.,2005(1):p.41-49.
[2]Boni C,Penna A,Bertoletti A,et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.J Clin Invest.1998;102:968-75.
[3]Milich DR.Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.J Viral Hepat.1997;4 Suppl 2:48-59.
[4]Tiegs G,Hentschel J,and Wendel A.A T cell-dependent experimental liver injury in mice inducible by concanavalin A.J Clin Invest.1992;90:196-203.
[5]Cantner F,Leist M,Lohse AW,et al.Concanavalin A induced T-cell-mediated hepatic injury in mice:the role of tumor necrosis factor.Hepatology.1995;21:190-8.
[6]Sabine K,Florian G,Gerald K,et al.Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by Concanavlin A.Gastroenterology.1996;111:462-71.
[7]Aderem A,and Ulevitch RJ.Tolll-like receptors in the induction of the innate immune response.Nature.2000;406:782-87.
[8]Hemmi H,Takeuchi O,Kawai T,et al.A toll-like receptor recognizes bacterial DNA,Nature.2000,408:740-745.
[9]Liu X,Xu Q,Chen W,et al.Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of nonmethylated CpG DNA.Oncology Reports.2009;21:941-47.
[10]Hartmann G.,Weeratna RD,Ballas ZK,et al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol.2000;164:1617-24.
[11]Krieg AM.CpG motifs in bacterial DNA and their immune effects.Annu Rev Immunol.2002;20:709-60.,
[12]Rutz M,Metzger J,Gellert T,et al.Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner.Eur J.Immunol.2004;34:2541-50.
[13]Bauer S,Kirschning CJ,Hacker H,et al.Human TLR9 confers responsiveness to bacterial DNA via secies-specific CpG motif recognition.Proc.Natl.Acad.Sci.U.S.A.2001;98:9237-42.
[14]Latz E,Schoenemeyer A,Visintin A,et al.TLR9 signals after translocating from the ER to CpG DNA in the lysosome.Nat.Immunol.2004;5:190-98.
[15]Comelie S,Hoebeke J,Schacht AM,et al.Direct evidence that Toll-like receptor 9)TLR9) functionally binds plasmid DNA by specific CpG motifs recognition.J.Biol.Chem.2004;279:15124-29
[16]Krieg AM,Yi AK,Schorr J,et al.The role of CpG dinucleotides in DNA vaccines.Trends Microbiol.1998;6:23-7.
[17]Klinman DM.Immunotherapeutic uses of CpG oligodeoxynucleotides.Nat.Rev.Immunol.2004;4:249-59.
[18]Juffermans NP,Leemans JC,Florquin S,et al.CpG oligodeoxynucleotides enhance host defense during murine tuberculosis.Infect.Imun.2002;70:147-52.
[19]Jorg V.and Arthur M.Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.Advanced Drug Delivery Review.2009;61:195-204
[20]McHutchison JG,Bacon BR,Gordon SC,et al.Relationships of HCV RNA responses to CpG 10101,a TLR9 agonist:pharmacodynamics & patient characteristics.AAASID.2005;abstract.
[21]Krie AM.Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides.Curr Oncol Rep.2004;6:88-95.
[22]Rankin R,Pontarollo R,Gomis S,et al.CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1glycoprotein D.Vaccine.2002;20:3014-22.
[23]Wernette CM,Smith BF,Barksdale ZL,et al.CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation.Vet Immunol Immunopathol.2002;84:223-36.
[24]Sven Klaschik,Debra Tross,and Nennis MK.Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.J Leukoc Biol.2009;Jan 29.Epub ahead of print.
[25]Kreig M,Vollmer J.Toll-like receptors 7,8 and 9:linking innate immunity to autoimmunity.Immunol.Rev.2007;220:251-69.
[26]Chaturvedi A,Dorward D,Pierce Sk.The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens.Immunity.2008;28:799-809.
[27]Sacher T,Knolle P,Nichteriein T,et al.CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol.2002;32:3628-37.
[28]Kim YI,Park JE,Martinez-Hernandez A,et al.CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1receptor-associated kinases.J Biol Chem.2008;283:15258-70.
[29]Slotta JE,Scheuer C,Menger M,et al.Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury,but provide a late window for protection against endotoxin-mediated liver damage.J Hepatol.2006;44:576-85.
[30]Yi AK,Yoon H,Park J,et al.CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice:the mitochondrial apoptotic pathway-dependent death of hepatocytes.J Biol Chem,2006.281:15001-12.
[31]Liu GT,Li Y,Wei HL,et al.Mechanism of protective action of bicyclol against CCl-induced liver injury in mice.Liver Int.2005;25:872-9.
[32]Li Y,Dai GW,Li Y,Liu GT.Effect of bicyclol on acetaminophen-induced hepatotoxicity:energetic metabolism and mitochondrial injury in acetaminophenintoxicated mice.Yao Xue Xue Bao.2001;36:723-6.
[33]Wang H and Li Y.Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol.2006;534:194-201.
[34]Zhao D and Liu GT.Protective effect of bicyclol on concanavalin A-induced liver nuclear DNA injury in mice.Zhonghua Yi Xue Za Zhi.2001;81:844-8.
[35]Li M and Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004;10:1775-9.
[36]Yu YN,Guo J,Li Y,et al.Effect of bicyclol on gene expression profiles in mice with liver injury induced by concanavalin A.Yao xue xue bao.2008;43:596-600.
[37]Liu GT.Bicyclol:a novel drug fro treating chronic viral hepatitis B and C.Med Chem.2009;5:29-43.
[38]Bao XQ,Liu GT.Induction of heat shock protein 27 and 70 overexpression by bicyclol attenuates concanavalin A-induced liver injury through suppression of NF-κB in mice.Mol pharmacol.2009;Epub ahead of print.
[39]Bao XQ,Liu GT.Bicyclol:a novel antihepatitis drug with hepatic heat shock protein 27/70-induceing activity and cytoprotective effects in mice.Cell stress chaperones.2008;13:347-55.
[40]Yu Z,Jiang H,Kan Q,et al.Dynamically analyzing on the anti-virus and hepatoprotective effects of bicyelol.China pharmaceuticals.2003;12:27-8.
[41]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei Med J.2002;43:657-64.
[42]Rico MA,Quiroga JA,Subir(?) D,et al.Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.Hepatology.2001;33:295-300.
[43]Boni C,Bertoletti A,Penna A,et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.J Clin Invest.1998;102:968-75.
[44]Milich DR.Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.J Viral Hepat.1997;4 Suppl 2:48-59.
[45]Muhanna N,Doron S,Wald O,et al.Activation of hepatic stellate cells after phagocytosis of lymphocytes:A novel pathway of fibrogenesis.Hepatology.200;48:963-77.
[46]Miyaaki H,Zhou H,Ichikawa T,et al.Study of liver-targeted regulatory T cells in hepatitis B and C virus in chronically infected patients.Liver Int,2008.Pub ahead of print.
[47]Zhang HH,Guo F,Fei R,et al.Inhibition of CD4+ CD25+ regulatory T cells in chronic hepatitis B patients.Zhonghua Yi Xue Za Zhi.2008;88:511-5.
[48]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei M ed J.2002;43:657-64.
[49]PromratK,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[50]ApolinarioA,MajanoPL,Alvarez-PtrezE,etal.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[51]Puren AJ,Fantozzi G,Dinarello CA.Gene expression,synthesis,and secretion of interleukin-18 and interleukin-beta are differentially regulated in homan blood mononuclear cells and mouse spleen cells.Proc Natl Acad Sci USA.1999;96:2256-61.
[52]Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18 biological properties and clinical implications.Eur Cytokine Netw.2000;11:15-25.
[53]Tsutsui H,Matsui K,Okamura H,et al.Pathophysiological roles of Interleukin-18 in inflammatory liver disease.Immunological Review.2000;174:192-209.
[54]Dinarello CA.Interleukin-18,a proinflammatory cytokine.Env Cytokine Netw.2000;1:483-86.
[55]Promrat K,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[56]ApolinarioA,MajanoPL,Alvarez-Ptrez E,et al.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[57]Duan ZP,Zhao XY,Huang DZ,et al.RANTES gene single nucleotide polymorphisms an d expression in patients with chr onic hepatitis B virus infection.Chin Med J(Engl).2005;118:909-14.
[58]Wagner H.Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity.Curr Opin M icrobiol.2002;5:62-69.
[59]Ashkar AA,Rosenthal K L.Toll-like receptor9,CpG DNA and innate immunity.Curr Mol Med.2002;2:545-56.
[60]Hemmi H,TakeuchiO,Kawai T,et al.A Toll-like receptor recognizes bacterial DNA.Nature.2000;408:740-745.
[61]Takeshita F,Gursel I,Ishii K J,et al.Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.Semin Immunol.2004;16:17-22.
[62]Verthelyi D,Zeuner RA.Differential signaling by CpG DNA in DC and B cells:not just TLR9.Trends Immuno.2003;21:519-22.
[63]Takeshita F,Leifer CA,Gursel I,et al.Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immnuno.2001;167:3555-8.
[64]Lee S,Hong J,Choi S,et al.CpG oligodeoxynucleotides induce expression of proinflammartory cytokines and chemokines in astrocytes:the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-κB activation.Journal of Neuroimmunology.2004;153:50-63.
[65]Shubing L,David JG,Angela MG,et al.Role of toll-like receptors in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with lipopolysaccharide.Infection and immunity.2002;70:3433-42.
[66]Hacher H,Vabulas RM,Takeuchi O,et al.Immune cell activation by bacterial CpG-DNA through myeroid differentiation marker 88 and tumor necrosisi factor receptor-associated factor(TRAF)6.J.Exp.Med.2000;192:595-600.
[67]Aderem A,Ulevitch RJ.Toll-like receptors in the induction of the innate immune response.Nature.2000;406:782-87.
[68]Elsharkawy AM,Mann DA.Nuclear factor-kappaB and the hepatic inflamm ation-fibrosis-cancer axis.Hepatology.2004;6:590-7.
[69]Christman JW,Lan caster LH,Blackwell TS.Nuclear factor kappa B:a pivotal role in the systemic inflammatory response syndrome and new target for therapy.Intensive Care Med.1998;24:1131-8.
[70]Shibolet O and D.K.Podolsky.TLRs in the Gut.Ⅳ.Negative regulation of Toll-like receptors and intestinal homeostasis:addition by subtraction.Am J Physiol Gastrointest Liver Physiol.2007;292:1469-73.
[71]Saklatvala J.Inflammatory signaling in cartilage:MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis.Curr Drug Targets.2007;8:305-13.
[1]Krieg AM,Yi AK,Matson S,et al.CpG motifs in bacterial DNA trigger direct B-cell activation.Nature.1995;374:546-549.
[2]Krieg AM,Yi AK,Schorr J,et al.The role of CpG dinucleotides in DNA vaccines.Trends Microbiol.1998;6:23-7.
[3]Hartmann G,Weeratna RD,Ballas ZK,et al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol.2000;164:1617-24.
[4]Medzhitov R,Janeway CA Jr.Innate immunity:impact on the adaptive immune response.Curr Opin Immunol.1997;9:4-9.
[5]Moser B,Loetscher P.Lymphocyte traffic control by chemokines.Nat Immunol.2001;2:123-8.
[6]Takeda K,Kaisho T,and Akira S.Toll-like receptors.Annu Rev Immunol.2003.21:335-76.
[7]Akira S and Takeda K.Toll-like receptor signalling.Nat Rev Immunol.2004;4:499-511.
[8]Xu N,Yao H,Sun Z,et al.Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma.Acta Pharmacol Sin.2008;29:239-44.
[9]Moser B and Loetscher p.Lymphocyte traffic control by chemokines.Nat.Immunol.2001;2:123-128.
[10]Krieg AM,Harmann G and Yi AK.Mechanism of action of CpG DNA.In Wagner,H.(Ed.) Current Topics in microbiology and immunology,vol.247.Springer,Berlin 2000;1-21
[11]Liu GT.Bicyclol:a novel drug for treating chronic viral hepatitis B and C.Med Chem.2009;5:29-43.
[12]Liu GT,Li Y,Wei HE,et al.Mechanism of protective action of bicyclol against CCl-induced liver injury in mice.Liver Int.2005;25:872-9.
[13]Li Y,Dai GW,Li Y,et al.Effect of bicyclol on acetaminophen-induced hepatotoxicity:energetic metabolism and mitochondrial injury in acetaminophen-intoxicated mice.Yao Xue Xue Bao.2001;36:723-6.
[14]Zhao D and Liu GT.Protective effect of bicyclol on concanavalin A-induced liver nuclear DNA injury in mice.Zhonghua Yi Xue Za Zhi.2001;81:844-8.
[15]Li M.and Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004;10:1775-9.
[16]Wang H and Li Y.Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol 2006;534:194-201.
[17]Bao XQ and Liu GT.Bicyclol:a novel antihepatitis drug with hepatic heat shock protein 27/70-inducing activity and cytoprotective effects in mice.Cell Stress Chaperones.2008;13:347-55.
[18]Bao XQ and Liu GT.Induction of heat shock protein 27 and 70 overexpression by bicyclol attenuates concanavalin A-induced liver injury through suppression of NF-{kappa}B in mice.Mol Pharmacol 2009;[Epub ahead of print]
[19]Wanless IR.Physioanatomic considerations.In:Schiff ER,Sorrell MF,Maddrey WC,eds.Schiff's Diseases of the Liver,8th edn.Philadelphia,PA:Lippincott-Raven Publishers,1998;16.
[20]Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and chemokines genes in human hepatoma cells.Yonsei Med J.2002;43:657-64.
[21]Rowell DL,Eckmann L,Dwinell MB,et al.Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion.Am J Physiol.1997;273:G322-32.
[22]Wegenka UM,Buschmann J,L(u|¨)tticken C,et al.Acute-phase response factor,a nuclear factor binding to acute-phase response elements,is rapidly activated by interleukin-6 at the posttranslational level.Mol Cell Biol.1993;13:276-88.
[23]Moshage H.Cytokines and the hepatic acute phase response.J Pathol.1997.181:257-66.
[24]Loomba R and Liang TJ.Treatment of chronic hepatitis B.Antivir Ther.2007;12 Suppl 3:H33-41.
[25]Gutierrez-Reyes G,Gutierrez-Ruiz MC,and Kershenobich D.Liver fibrosis and chronic viral hepatitis.Arch Med Res.2007;38:644-51.
[26]Promrat K,McDermott DH,Gonzalez CM,et al.Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Gastroenterology.2003;124:352-60.
[27]Apolinario A,Majano PL,Alvarez-P(?)rez E,et al.Increased expression of T cell chemokines and their receptors in chronic hepatitis C:relationship with the histological activity of liver disease.Am J Gastroenterol.2002;97:2861-70.
[28]Duan ZP,Zhao XY,Huang DZ,et al.RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection.Chin Med J(Engl).2005;118:909-14.
[29]Masihi KN.Novel concepts for anti-infective activity of cytokines,chemokines and diverse agents.Recent Pat Antiinfect Drug Discov.2006;1:147-56.
[30]Cheong JY,Cho SW,Choi JY,et al.RANTES,MCP-1,CCR2,CCR5,CXCR1and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection.results from a large scale single ethnic population.J Korean Med Sci.2007;22:529-35.
[31]Tilg H,Kaser A,and Moschen AR.How to modulate inflammatory cytokines in liver diseases.Liver Int.2006;26:1029-39.
[32]Zou Z,Li B,Xu D,et al.Imbalanced Intrahepatic Cytokine Expression of Interferon-gamma,Tumor Necrosis Factor-alpha,and Interleukin-10 in Patients With Acute-on-Chronic Liver Failure Associated With Hepatitis B Virus Infection.J Clin Gastroenterol.2009;43:182-90
[33]Falasca K,Ucciferri C,Dalessandro M,et al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C.Ann Clin Lab Sci.2006;36:144-50.
[34]Lebel-Binay S,Berger A,Zinzindohou(?) F,et al.Interleukin-18:biological properties and clinical implications.Eur Cytokine Netw.2000;11:15-26.
[35]Tsutsui H.Matsui K,Okamura H,et al.Pathophysiological roles of interleukin-18 in inflammatory liver diseases.Immunol Rev.2000;174:192-209.
[36]Dinarello CA,Interleukin-18,a proinflammatory cytokine.Eur Cytokine Netw.2000;11:483-6.
[37]Yi AK,Yoon H,Park JE,et al.CpG DNA-mediated induction of acute liver injury in D-Galactosamine-sensitized mice.The Journal of biological chemistry.2006;281:15001-12.
[38]Kazumichi A,Hiromasa O,Hiroko K,et al.Role of CpG ODN in concanavalin A-induced hepatitis in mice.Fukushima J.Med.Sci..2005;51:41-9.
[39]Lim EJ,Lee SH,Lee JG,et al.Toll-like receptor 9 dependent activation of MAPK and NF-κB is required for the CpG ODN-induced matrix metalloproteinase-9 expression.Experimental and molecular medicine.2007,39:239-46.
[40]Lim E J,Lee SH,Lee JG,et al.Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.FEBS Lett.2006;580:4533-8.
[41]Osawa Y,Iho S,Takauji R,et al.Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells.The Journal of Immunology.2006,177:4841-52.
[42]Kawai T and Akira S.Signaling to NF-kappaB by Toll-like receptors.Trends Mol Med.2007;13:460-9.
[43]Yang K,Puel A,Zhang S,et al.Human TLR-7,-8,and-9-mediated induction of IFN-alpha/beta and-lambda is IRAK-4 dependent and redundant for protective immunity to viruses.Immunity.2005;23:465-78.
[1]刘耕陶.国家一类抗肝炎新药双环醇片.传染病信息,2002,15:3-4.
[2]Wang H,Li Y.Protective effect of bicyclol on actute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.Eur J Pharmacol,2006,534:194-201.
[3]李敏,刘耕陶.双环醇对脂多糖诱导巨噬细胞iNOs蛋白的表达和NF-κB 的抑制作用.中国药理学通报,2006,22:1438-43.
[4]刘耕陶,李敏,孙华,等.一类抗肝炎新药双环醇药理研究的新进展.中国药理通讯,2005,22:1-2.
[5]莫成林,李烨,李燕.双环醇对小鼠慢性酒精性肝损伤的保护作用.中华医学杂志,2005,85:3409-3413.
[6]Lu H,Li Y.Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats.Acta Pharmacol Sin.2002,23:942-945.
[7]陈燕琴,高同军,迟俭,等.双环醇片治疗抗结核药物性肝损害临床疗效和安全性分析.传染病信息,2005,18:188-189.
[8]Liu GT,Li Y,Wei HL,et al.Mechanism of protective action of bicyclol against CC14-induced liver injury in mice.Liver Int.2005,25:872-879.
[9]刘耕陶.双环醇的抗病毒与肝细胞保护作用及其作用机制.中国新药杂志,2001,10:325-327.
[10]赵冬梅,刘耕陶.双环醇对刀豆蛋白A所致小鼠肝细胞核DNA损伤的保护作用.中华医学 杂志,2001,81(14):844-848.
[11]Li M,Liu GT.Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol.World J Gastroenterol.2004,10:1775-1779.
[12]李烨,戴国炜.双环醇对扑热息痛引起的小鼠肝脏能量代谢和线粒体功能障碍的影响.药学学报,2001,36:723-726.
[13]赵冬梅,刘耕陶.双环醇对乙酰氨基酚致小鼠肝线粒体损伤的保护作用.中国新药杂志,2002,11:536-540.
[14]Liu GT,Zheng CZ,Li Y,et al.Clinical and pharmacological study of bicyclol-a potential anti chronic viral hepatitis drug.Clin Med Sci J,1999;14:51-53.
[15]Yang XY,Zhou Q,Wu TX,et al.Bicyclol for chronic hepatitis C.Cochrane Database Syst Rev.2007,24:CD004994.
[16]余祖江,江河清,阚全程,等.双环醇抗病毒与保护肝细胞作用的动态观察和分析.中国药业,2003,12:27-28.
[17]Rehermann B,Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol,2005,5:215-218.
[18]吴兴柳,王鸿香,钟根钳.双环醇与拉米夫定联合治疗慢性乙型肝炎的临床疗效及对T细胞亚群的影响.中国医院用药评价与分析.2005,5:235-237.
[19]施斌斌,彭颉,温帆渊,等.百赛诺对慢性乙型肝炎患者细胞免疫应答的影响.第一军医大学学报,2005;25:706-708.
[20]Hu QW,Liu GT.Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action.Life Sci.,2006,79:606-612.
[21]韩春荣,何生松,徐标.双环醇对小鼠日本血吸虫病肝组织即早基因与TGF-β1表达的影响.中国病原生物学杂志,2006,1:434-437.
[22]易建华,李伟,曾令兰,罗端德.双环醇治疗慢性乙型病毒性肝炎肝纤维化及其作用机制.大连大学学报,2006,27:27-30.
[23]李烨,李燕,刘耕陶.双环醇对实验性肝纤维化的防护作用及分子机制.中华医学杂志,2004,84:2096-2010.
[24]鞠美华,李燕.双环醇在大鼠和人肝微粒体的代谢.药学学报,2005,40:111-116.
[25]Liu Q,Song Y,Zhou Y,et al.A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther,2006;5:1674-6.
[26]Zhu B,Liu GT,Wu RS,et al.Chemoprevention of bicyclol against hepatic preneoplastic lesions.Cancer Biol Ther,2006;5:1665-73.
[27]Hua Sun,Geng-Tao Liu.Chemopreventive effect of bicyclol on malignant transformation of WB-F344 rat liver epithelial cells and its effect on related signal transduction in vitro.Cancer Letters,2006,236:239-249.
[28]赵冬梅,孙韬,李燕.双环醇对大鼠肾脏缺血-再灌注损伤的保护作用.药学学报,2002,37:412-414.
[29]Pan SY,Dong H,Yu ZL,et al.Bicyclol,a synthetic dibenzocyclooctadiene derivative,decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.Pharm Pharmacol.2007,59:1657-1662.
[30]唐韬,李烨,李燕.双环醇对小鼠非酒精性肝病的保护作用和机制研究.中国药理通讯,2005,22:53-55.
[31]王建军,成军,刘妍,等.基因表达谱芯片筛选双环醇作用HepG2细胞后的差异表达基因.世界华人消化杂志,2004,12:1711-1714.
[32]郭江,纪冬,成军,等.双环醇下调细胞周期素B2基因启动子转录活性研究.胃肠病原菌学和肝病学杂志,2005,14:346-348.
[1]Bauer,S.,et al.,Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.Proc Natl Acad Sci U S A,2001.98(16):p.9237-42.
[2]Krieg,A.M.,et al.,CpG motifs in bacterial DNA trigger direct B-cell activation.Nature,1995.374(6522):p.546-9.
[3]Krieg,A.M.,CpG motifs in bacterial DNA and their immune effects.Annu Rev Immunol,2002.20:p.709-60.
[4]Yi,A.K.,et al.,Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.Int Immunol,2001.13(11):p.1391-404.
[5]Hacker,H.,et al.,Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells.Ernbo J,1999.18(24):p.6973-82.
[6]Hartmann,G.and A.M.Krieg,Mechanism and function of a newly identified CpG DNA motif in human primary B cells.J Immunol,2000.164(2):p.944-53.
[7]Sun,S.,et al.,Type Ⅰ interferon-mediated stimulation of T cells by CpG DNA.J Exp Med,1998.188(12):p.2335-42.
[8]Bendigs,S.,et al.,CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells.Eur J Immunol,1999.29(4):p. 1209-18.
[9]Takeshita,S.,et al.,CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression.Cell Immunol,2000.206(2):p.101-6.
[10]Sester,D.P.,et al.,Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.J Immunol,2000.165(8):p.4165-73.
[11]Yi,A.K.,et al.,Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production:central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Thl response.J Immunol,2002.168(9):p.4711-20.
[12]Hartmann,G.,et al.,CpG DNA:a potent signal for growth,activation,and maturation of human dendritic cells.Proc Natl Acad Sci U S A,1999.96(16):p.9305-10.
[13]Krieg,A.M.,et al.,The role of CpG dinucleotides in DNA vaccines.Trends Microbiol,1998.6(1):p.23-7.
[14]Hartmann,G.,et al.,Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.J Immunol,2000.164(3):p.1617-24.
[15]Rankin,R.,et al.,CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D.Vaccine,2002.20(23-24):p.3014-22.
[16]Wernette,C.M.,et al.,CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation.Vet Immunol Immunopathol,2002.84(3-4):p.223-36.
[17]Sfondrini,L.,et al.,Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA.Faseb J,2002.16(13):p.1749-54.
[18]Wagner,H.Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity.Curr Opin Microbiol,2002,5(1):62-69.
[19]Ashkar,AA,and Rosenthal,K.L.,Toll-like receptor 9,CpG DNA and innate immunity.Curr Mol Med,2002,2(6):545-556.
[20]Heeg,K.,Zimmermann S.CpG DNA as a Th1 trigger.Int Arch Allergy Immunol,2000,121(2):87-97.
[21]Hemmi,H.,et al.,A Toll-like receptor recognizes bacterial DNA.Nature.2000;408(6813):740-5.
[22]Takeshita,F.,et al.,Cutting edge:role of toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immunol,2001,167(7):3555-3558.
[23]Chuang,T.H.,et al.,Toll-like receptor 9 mediates CpG-DNA signaling.J Leukoc Biol,2002,71(3):538-544.
[24]Hornung,V.,et al.,Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.J Immunol,2002.168(9):p.4531-7.
[25]Dalpke,A.H.,et al.,Immunostimulatory CpG-DNA activates murine microglia.J Immunol,2002.168(10):p.4854-63.
[26]Takeshita,F.,et al.,Cutting edge:Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.J Immunol,2001.167(7):p.3555-8.
[27]Verthelyi,D.and R.A.Zeuner,Differential signaling by CpG DNA in DCs and B cells:not just TLR9.Trends Immunol,2003.24(10):p.519-22.
[28]Bauer,S.,et al.,Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition,in Proc Natl Acad Sci U S A.2001.p.9237-42.
[29]Wager H.Toll meets bacterial CpG DNA.Immunity,2001,14:499-502.
[30]Ahmad-Nejad,P.,et al.,Bacterial CpG DNA and lipopolsaccharides activate toll-like receptor at distinct cellular compartments.Eur J Immunol,2002,31(7):1958-1968.
[31]Leifer,C.,et al.,TLR9 is localized in the endoplasmic reticulum prior to stimulation.J Immunol,2004,173(2):1179-1183.
[32]Latz,E.,et al.,TLR9 signals after translocating from the ER to CpG DNA in the lysosome.Nat Immunol,2004.5(2):p.190-8.
[33]Krieg,A.M.,Now I know my CpGs.Trends Microbiol,2001.9(6):p.249-52.
[34]Medzhitov,R.,CpG DNA:security code for host defense.Nat Immunol,2001.2(1):p.15-6.
[35]Krieg,A.M.and H.Wagner,Causing a commotion in the blood:immunotherapy progresses from bacteria to bacterial DNA.Immunol Today,2000.21(10):p.521-6.
[36]Hacker,H.,et al.,Immunce cell activation by bacterial CpG DNA through myeloid differentiation factor(TRAF)6.J Exp Med,2000,192(4):595-699.
[37]Yi,A.K.,et al.,Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production:central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response.J Immunol,2002,16899:4711-20.
[38]Hoshino,K.,,et al.,Differential involvement of IFN-b in Toll-like receptor-stimulated dendritic cell activation.Int Immunol,2002,14(10):1225-31.
[39]Park,Y.,S.W.Lee,and Y.C.Sung,Cutting Edge:CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway.J Immunol,2002.168(1):p. 5-8.
[40]Cowdery,J.S.,et al.,Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides.J Immunol,1996.156(12):p.4570-5.
[41]Sparwasser,T.,et al.,Macrophages sense pathogens via DNA motifs:induction of tumor necrosis factor-alpha-mediated shock.Eur J Immunol,1997.27(7):p.1671-9.
[42]Sacher,T.,et al.,CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol,2002.32(12):p.3628-37.
[43]Yi,A.K.,et al.,CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice:the mitochondrial apoptotic pathwaydependent death of hepatocytes.J Biol Chem,2006.281(21):p.15001-12.
[44]Kim,Y.I.,et al.,CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1 receptor-associated kinases.J Biol Chem,2008.283(22):p.15258-70.
[45]Kaxumichi,A.,et al.,Role of CpG ODN in concanavalin A-induced hepatitis in mice.Fukushima J.Med.Sci.,2005(1):p.41-49.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |